Analysts Set Zenas BioPharma, Inc. (NASDAQ:ZBIO) Target Price at $44.29

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $44.2857.

A number of equities analysts have recently weighed in on ZBIO shares. HC Wainwright reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Zacks Research raised Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Friday, March 27th. Guggenheim upped their price target on Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Finally, Citigroup reiterated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd.

Insider Buying and Selling

In related news, CEO Leon O. Moulder, Jr. purchased 60,000 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was acquired at an average price of $16.88 per share, for a total transaction of $1,012,800.00. Following the completion of the acquisition, the chief executive officer owned 96,928 shares of the company’s stock, valued at $1,636,144.64. This represents a 162.48% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Fairmount Funds Management Llc purchased 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 31st. The shares were bought at an average price of $20.00 per share, with a total value of $3,000,000.00. Following the acquisition, the director directly owned 2,359,025 shares of the company’s stock, valued at $47,180,500. This represents a 6.79% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 273,768 shares of company stock worth $5,150,198. 22.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zenas BioPharma

Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in Zenas BioPharma by 4.6% in the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after purchasing an additional 16,461 shares during the last quarter. Rhumbline Advisers boosted its position in Zenas BioPharma by 71.3% in the second quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after purchasing an additional 8,207 shares during the last quarter. Sei Investments Co. purchased a new position in Zenas BioPharma in the second quarter worth $118,000. Bank of America Corp DE boosted its position in Zenas BioPharma by 32.3% in the second quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock worth $136,000 after purchasing an additional 3,412 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Zenas BioPharma by 17.2% in the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock worth $25,813,000 after purchasing an additional 170,546 shares during the last quarter.

Zenas BioPharma Price Performance

Shares of NASDAQ:ZBIO opened at $19.80 on Tuesday. The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04. Zenas BioPharma has a twelve month low of $8.91 and a twelve month high of $44.60. The stock’s 50 day moving average is $19.44 and its 200-day moving average is $24.67. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -2.34 and a beta of -0.71.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. During the same period last year, the business earned ($0.80) EPS. Sell-side analysts forecast that Zenas BioPharma will post -4.47 EPS for the current fiscal year.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.